<u>Amendments to the Claims:</u> Please delete claim 1-48 and add new claims 49-69. This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. - 48. (Canceled)

49. (New) A composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

wherein,

Ar¹ is a substituted or unsubstituted heteroaryl group selected from indolyl, substituted indolyl, benzofuranyl, substituted benzofuranyl, furanyl, substituted furanyl, substituted thienyl, isothiazolyl, substituted isothiazolyl, pyrazolyl, and substituted pyrazolyl and substituted phenyl

such that when Ar^1 is substituted heteroaryl it bears a substituent which is selected from halogen, alkyl, halo(C_1 - C_4)alkyl, (C_1 - C_4)alkoxy, halo(C_1 - C_4)alkoxy, nitro, cyano, -NR⁷C(O)R⁸, -NR⁷R⁸, phenyl and substituted phenyl, and

when Ar¹ is substituted phenyl it bears a substituent which is selected from halogen, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, halo(C₁-C₄)alkoxy, nitro, cyano, -NR⁷R⁸, phenyl and substituted phenyl, wherein

R⁷ and R⁸ are members independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl, or R⁷ and R⁸ taken together with the nitrogen to which each is attached form a 5-,

6- or 7-membered ring optionally having additional heteroatoms at the ring vertices.;

X is a member selected from the group consisting of O, S and N-R¹, wherein,

 R^1 is a member selected from the group consisting of H, (C_1-C_8) alkyl, substituted (C_1-C_8) alkyl, heteroalkyl, substituted heteroalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl (C_1-C_4) alkyl, substituted aryl (C_1-C_4) alkyl, CN, $-C(O)R^2$, $-OR^3$, $-C(O)NR^3R^4$, and $-S(O)_2NR^3R^4$.

wherein,

R² is a member selected from the group consisting of (C₁-C₈)alkyl, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, alkaryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl;

R³ and R⁴ are each members independently selected from the group consisting of hydrogen, (C₁-C₀)alkyl, substituted (C₁-C₀)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl, or R³ and R⁴ can be combined with the nitrogen to which each is attached to form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices; and

Y is a member selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ substituted alkyl, -OCH₃ and -OCF₃.

- 50. (New) The method according to claim 49, wherein X is O.
- 51. (New) The method according to claim 49, wherein Ar¹ is a member selected from the group consisting of substituted or unsubstituted 2-indolyl and substituted or unsubstituted 2-thienyl.
- 52. (New) A composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

wherein,

Ar¹ is substituted phenyl bearing a substituent –NC(O)R⁷R⁸, wherein

R⁷ and R⁸ are members independently selected from the group consisting of hydrogen, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl, or R⁷ and R⁸ taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices.;

X is a member selected from the group consisting of O, S and N-R¹, wherein,

 R^1 is a member selected from the group consisting of H, (C_1-C_8) alkyl, substituted (C_1-C_8) alkyl, heteroalkyl, substituted heteroalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl (C_1-C_4) alkyl,

substituted aryl(C_1 - C_4)alkyl, CN, $-C(O)R^2$, $-OR^3$, $-C(O)NR^3R^4$, and $-S(O)_2NR^3R^4$,

wherein,

R² is a member selected from the group consisting of (C₁-C₈)alkyl, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, alkaryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl;

R³ and R⁴ are each members independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl, or R³ and R⁴ can be combined with the nitrogen to which each is attached to form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices; and

Y is a member selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ substituted alkyl, -OCH₃ and -OCF₃.

53. (New) A composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

$$Ar^1$$
 N
 N
 N

wherein,

Ar¹ is substituted or unsubstituted multiple ring aryl, wherein Ar¹ substituents are members selected from the group consisting of halogen, alkyl, halo(C₁-C₄)alkyl, (C₁-C₄)alkoxy, halo(C₁-C₄)alkoxy, nitro, cyano, -NR⁷C(O)R⁸, -NR⁷R⁸, phenyl and substituted phenyl,

R⁷ and R⁸ are members independently selected from the group consisting of hydrogen, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl, or R⁷ and R⁸ taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices;

X is a member selected from the group consisting of O, S and N-R¹, wherein,

 R^1 is a member selected from the group consisting of H, (C_1-C_8) alkyl, substituted (C_1-C_8) alkyl, heteroalkyl, substituted heteroalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl (C_1-C_4) alkyl, substituted aryl (C_1-C_4) alkyl, CN, $-C(O)R^2$, $-OR^3$, $-C(O)NR^3R^4$, and $-S(O)_2NR^3R^4$,

wherein,

R² is a member selected from the group consisting of (C₁-C₈)alkyl, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, alkaryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl;

R³ and R⁴ are each members independently selected from the group consisting of hydrogen, (C₁-C₈)alkyl, substituted (C₁-C₈)alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C₁-C₄)alkyl and substituted aryl(C₁-C₄)alkyl, or R³ and R⁴ can be combined with the nitrogen to which each is attached to form a 5-, 6- or 7-membered ring optionally having additional heteroatoms at the ring vertices; and

Y is a member selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ substituted alkyl, -OCH₃ and -OCF₃.

54. (New) A composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

wherein,

Y is a member selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ substituted alkyl, -OCH₃ and -OCF₃; and

R⁵ and R⁶ are members independently selected from the group consisting of H, halogen, substituted or unsubstituted alkyl, halo(C₁-C₄)alkyl, nitro, cyano and substituted or unsubstituted phenyl, with the proviso that both R⁵ and R⁶ are not H.

55. (New) The composition according to claim 54, wherein R⁵ and R⁶ are members independently selected from the group consisting of H, F, and Cl, with the proviso that both R⁵ and R⁶ are not H.

56. (New) A composition comprising a pharmaceutically acceptable excipient and a compound of the formula:

$$\mathbb{R}^{1,W} \mathbb{Z} \xrightarrow{Q} \mathbb{H} \mathbb{H} \mathbb{H}$$

wherein Y is a member selected from methyl, trifluoromethoxy, -CF₃ or halo;

V and X are members independently selected from H, halo, substituted or

unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, NO₂,

CN, CF₃, C(O)NR¹¹R¹² and C(O)R¹³;

R¹, R¹¹, R¹² and R¹³ are members independently selected from substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted or unsubstituted heterocycle, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, in which R¹¹ and R¹² optionally can be joined into a ring;

Q and W are members independently selected from -(CR^2R^3)_t-(CH_2)_n-,

 $-(CH_2)_n-(CR^2R^3)_t$, $-C(R^4)=C(R^5)$ -, and -C=C- wherein

R² and R³ are members independently selected from H, F, substituted or unsubstituted lower alkyl or substituted or unsubstituted lower heteroalkyl, in which R² and R³ are optionally joined to form a cyclic structure which is a member selected from the group consisting of cycloalkyl and heterocycle groups, or R² and R³ together with the carbon to which they are attached form -C(O)-;

Z is a member selected from -O-, $-S(O)_{m^-}$, $-N(R^4)$ -, $-N(R^4)C(O)$ -, $-C(O)N(R^4)$ -, -C(O)-, $-N(R^4)C(O)N(R^5)$ -, $-N(R^4)C(O)O$ -, $(CR^2R^3)_t$, and $-SO_2N(R^4)$ -, wherein

R⁴ and R⁵ are members independently selected from the group consisting of H, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, in which R¹ is optionally joined together with either X or R⁴ to form a substituted or unsubstituted heterocycle;

m is an integer from 0 to 2, inclusive; n is an integer from 0 to 3, inclusive; and t is an integer from 0 to 2, inclusive.

- 57. (New) The composition according to claim 56, wherein Y is a member selected from chloro and methyl.
- 58. (New) The composition according to claim 56, wherein V and X are members independently selected from the group consisting of H, halo, substituted or unsubstituted lower alkyl, and -CF₃.
- 59. (New) The composition according to claim 56, wherein Z is a member selected from the group consisting of -S-, SO_2 -, $-(CR^2R^3)_t$ -, and -O-.
- 60. (New) The composition according to claim 58, wherein Z is a member selected from the group consisting of -S-, SO_2 -, $-(CR^2R^3)_t$ -, and -O-.
 - 61. (New) The composition according to claim 56, wherein R⁴ is H.
- 62. (New) The composition according to claim 58, wherein R¹ is a member selected from the group consisting of:

- 63. (New) The method according to claim 58, wherein n is an integer from 0 to 2, inclusive; and t is an integer from 0 to 1, inclusive.
- 64. (New) The composition according to claim 56, wherein said compound has a structure which is a member selected from the group consisting of the compounds set forth in FIG. 1.
- 65. (New) The composition according to claim 56, wherein said compound has the structure:

$$X$$
 R^6
 N
 N
 N

wherein

R¹-W-Z-Q- is R⁶, and R⁶ is selected from the group consisting of H, halogen, substituted or unsubstituted alkyl, halo(C₁-C₄)alkyl, nitro, cyano, substituted or unsubstituted phenyl, R⁹O-; R⁹S-; R⁹NH-; R⁹NH-; R⁹NHS(O)₂-; R⁹S(O)₂-, with the proviso that both X and R⁶ are not H;

wherein R⁹ is a member selected from aryl, and alkylaryl, when there is more than one R⁹ group per molecule, each R⁹ group is independently selected; and

Y is a member selected from halogen, C₁-C₄ alkyl, -OCH₃, and -OCF₃.

- 66. (New) The composition according to claim 65, wherein the alkyl component of said alkylaryl group is a C_1 - C_4 alkyl group.
- 67. (New) The composition according to claim 65, wherein said aryl group of R⁹ is heteroaryl.
- 68. (New) The composition according to claim 65, wherein the aryl component of said (C_1-C_4) alkylaryl group is a substituted or unsubstituted aryl group.
- 69. (New) The composition according to claim 65, wherein the aryl component of said (C_1-C_4) alkylaryl group is a substituted or unsubstituted heteroaryl group.